MC5R and heart failure: Finally, to evaluate the therapeutic potential of targeting MC5-R for the management of heart failure, we employed the TAC-model in C57Bl/6N mice that are more prone to develop TAC-induced heart failure (Garcia-Menendez et al, 2013; Zi et al, 2019) and treated the mice with PG-901 at two different dose levels (0.005 or 0.5 mg/kg/day).